The same INN can appear on two very different articles of commerce: an FDA-approved finished injection product and a research-use lyophilized powder. This page separates those classes. It is not a product page, not a What-Is identity essay, and not a comparison of receptor counts.
Research listing (soft): tirzepatide catalog. CoA literacy: Quality.
What is tirzepatide as a molecule?
Tirzepatide is a synthetic dual agonist at the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). Discovery and early clinical proof-of-concept work used the development code LY3298176 (Coskun et al., Molecular Metabolism, 2018; PMID 30473097). That paper describes dual GIP and GLP-1 receptor agonist activity — not a triple agonist.
What does “approved drug product” mean here?
An approved drug product is a finished dosage form cleared through an FDA NDA pathway, with labeling, manufacturing controls, and prescribing information under that application.
For tirzepatide injection, FDA approved NDA 215866 on May 13, 2022 (approval letter: FDA). This page cites that letter for the fact that approved tirzepatide injection product(s) exist under that NDA. It does not paste indications, does not instruct patients, and does not treat other NDAs as the same application. A later branded product for a different indication may sit under a separate NDA (for example NDA 217806); do not collapse distinct NDAs into one.
What does “research-grade” mean here?
Research-grade tirzepatide on a research supplier page means lyophilized peptide intended for in-vitro / laboratory research, sold research-use-only, and documented by a batch Certificate of Analysis (HPLC purity, LC-MS/MS or other identity data, testing laboratory, dates, lot/accession as printed). Quality expectations are lot-level analytics, not a drug label. How to read a peptide CoA: Quality.
Why aren't they interchangeable?
| Approved injection product (NDA pathway) | Research-grade lyophilized powder (RUO) | |
|---|---|---|
| Intended use | Labeled finished drug product under FDA NDA | Laboratory / in-vitro research only |
| Quality frame | Drug labeling + NDA controls | Lot CoA fields on the certificate |
| Supply | Regulated finished dosage form | Research chemical / peptide supply |
| Human use | Per approved labeling only | Not for human or veterinary use |
Shared chemistry language (INN / code) does not make a research vial an approved drug product. This page does not claim clinical sameness or interchangeability for research powder.
What should a lab document on receipt?
Record the size selected, lot (as printed), CoA accession, measured HPLC, identity method, laboratory name, and report dates from the certificate panel for that size. Match the vial lot to the CoA lot. If a size has no certificate on file, that size has no lot document yet — do not borrow another size's CoA. Details: Quality. Soft listing: catalog.
Related pages
- Research listing: Tirzepatide catalog
- CoA literacy: Quality
- Triple vs dual (mechanism only, thin): Retatrutide vs tirzepatide
Frequently Asked Questions
Is research-grade tirzepatide the same as the approved drug product?+
What does LY3298176 refer to?+
Which FDA application covers an approved tirzepatide injection product?+
How do I verify a research lot?+
Does this page recommend human use of research powder?+
References
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist… Molecular Metabolism. 2018;18:3-14. PMID: 30473097.
- U.S. FDA. NDA 215866 approval letter (tirzepatide injection), May 13, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215866Orig1s000ltr.pdf